Genedrive Share Discussion Threads

[snowy20] 07/7/2022 08:40

GDR have put out intra day rns . Keep watch can happen .

[snowy20] 07/7/2022 08:37

Well financed this year. approx £6 million in bank number months past. NHS AIHL RNS even this week or soon ,Good chance Back to £1 ,

This week seen how fast can rise .July now buyers back at GDR . Some had predicted July gdr move up .Started off well .

[danessex] 07/7/2022 07:14

Don't look like it. Another red day

[snowy20] 06/7/2022 16:32

Has time arrived for NHS orders .Have this Weeks 100k buyers loading for this news

Will it be AIHL RNS
Around 300 nurses are being trained to use the machine across MFT at Saint Mary’s Hospital, Wythenshawe Hospital, and North Manchester General Hospital, and the test is expected to be routinely used in all the hospitals’ neonatal units within weeks, which are part of Saint Mary’s Managed Clinical Service within the Trust.

[snowy20] 06/7/2022 16:28

Buying before end of day .Buyers who want shares before next RNS .

Well financed this year. approx £6 million in bank number months past. NHS AIHL RNS even this week or soon ,Good chance Back to £1 ,50K buyer buying so many shares .

[snowy20] 06/7/2022 16:26

Rise this Week was forseeable .Some unhappy they not bought in .

[snowy20] 06/7/2022 16:22

Buyers piling in .

[milanr] 06/7/2022 16:12

FINANCIAL HIGHLIGHTS -- No revenue in the period, (31 Dec 2020: GBP0.4m) owing to delayed product development -- Operating loss of GBP2.8m (31 Dec 2020: GBP2.9m) -- R&D spend reduced to GBP1.9m (31 Dec 2020: GBP2.3m)

[danessex] 06/7/2022 15:48

You crack me up. People be carefully blindly listening to people like this people been saying a pound for years

[snowy20] 06/7/2022 15:27

GDR moved up so quickly this week . Relatively low number of shares in Issue .

GDR let out that RNS to see how much it moves .

[snowy20] 06/7/2022 15:05

Watch for buying before end of day .Buyers who want shares before next RNS .

Well financed this year. approx £6 million in bank number months past. NHS AIHL RNS even this week or soon ,Good chance Back to £1 ,50K buyer buying so many shares .

[mdw1] 06/7/2022 15:04

Worth a top up at these levels, definitely something going on behind the scenes

[snowy20] 06/7/2022 14:20

Mike Hobday, Director of Policy and Campaigns at the National Deaf Children’s Society, said: “The National Deaf Children’s Society welcomes the publication of this important study. The introduction of a rapid test to identify susceptibility to deafness caused by the antibiotic gentamicin will be greatly valued by many families of newborn babies.

“Up to now the genetic test has taken too long to return from the lab to be useful for babies requiring urgent treatment but a rapid test will be a game-changer”.

[snowy20] 06/7/2022 14:18

Professor Dame Sue Hill, Chief Scientific Officer for England and Senior Responsible Officer for Genomics in the NHS, said: “Genomic medicine is transforming healthcare, and this is a powerful example of how genetic testing can now be done extremely quickly and become a vital part of triage – not only in intensive care but across our services.

“It also shows the importance of thinking about how advances in technology can rapidly transform how we use genomics closer to care for our patients.”

Professor Newman, who is Associate Lead, Hearing Health Genomic Solutions at NIHR Manchester Biomedical Research Centre (BRC), said the team had successfully transferred the accuracy of the machine in the lab to working effectively in a ward. At the same time, clinicians adapted quickly to incorporate the test into their routine care for very sick children in the neonatal ward.

The idea for the test came five years ago, and trials started in 2020 with further adaptations and fine-tuning so that the current machine, which is called the Genedrive System, is now fully CE certified to be used in a clinical setting.

Study results were published in JAMA Pediatrics – the top-ranked paediatrics journal in the world – last week.

Backed by £900,000 funding from the National Institute for Health Research (NIHR) and support from the charity Royal National Institute for Deaf People, the Genedrive System, which costs £80 per baby, was developed by Genedrive, a start-up based at the University of Manchester. It was developed in close collaboration with Professor Newman’s team at Manchester Biomedical Research Centre.

[snowy20] 06/7/2022 14:03

The Rise this week should not have caught you out .Was to expected . Watch for more of a rise .

[milanr] 06/7/2022 13:55

FINANCIAL HIGHLIGHTS -- No revenue in the period, (31 Dec 2020: GBP0.4m) owing to delayed product development -- Operating loss of GBP2.8m (31 Dec 2020: GBP2.9m) -- R&D spend reduced to GBP1.9m (31 Dec 2020: GBP2.3m)

[snowy20] 06/7/2022 13:55

No Suprise share price started to rise .
Has time arrived for NHS orders .are 100k buyers loading for this news

Will it be AIHL RNS
Around 300 nurses are being trained to use the machine across MFT at Saint Mary’s Hospital, Wythenshawe Hospital, and North Manchester General Hospital, and the test is expected to be routinely used in all the hospitals’ neonatal units within weeks, which are part of Saint Mary’s Managed Clinical Service within the Trust.

[snowy20] 06/7/2022 13:52

They did predict rise in July .It started .

[snowy20] 06/7/2022 13:44

Risee this Week Obviously caught some out .GDR let it go to see how high share price moves .Some not want to be out before end of day .

[milanr] 06/7/2022 13:40

You must be deep under water, what do you smoke ?

[snowy20] 06/7/2022 13:38

Well financed this year. approx £6 million in bank number months past. NHS AIHL RNS even this week or soon ,Good chance Back to £1 ,50K buyer buying so many shares .Another small blue Finish from buyers loading up before RNS

This week how fast can rise .July now buyers back at GDR .

[milanr] 06/7/2022 13:32

Budd should be great full first and only to the shareholders, for keeping the company above with water with new share placings, he is great full as he keep getting his full salary and bonuses. Similar to Boris, no shame

[snowy20] 06/7/2022 13:28

NICE to evaluate the Genedrive® MT-RNR1 Test under their Diagnostics Assessment Programme



genedrive plc (AIM: GDR), the near patient molecular diagnostics company, announces that the UK's National Institute for Health and Clinical Excellence ('NICE') has started an evaluation of the Genedrive® MT-RNR1 test via their Diagnostics Assessment Programme ('DAP'). DAP evaluations are designed to provide robust recommendations on the use of new products, which is presented in the form of NICE guidance, and to promote rapid and consistent adoption of clinically innovative and cost-effective diagnostic technologies in the NHS.



An independent advisory committee considers the evidence provided, makes draft recommendations for public consultation and ultimately makes final recommendations for publication in NICE guidance. The guidance produced is used by NHS commissioners, practitioners, healthcare operational managers and purchasing and procurement organisations.



genedrive's assay is the world's first rapid point of care test to screen infants in an urgent care setting for a genetic variant that will cause life-long hearing loss when carriers of the variant are given certain antibiotics. Those that carry the variant can then be given alternative treatments following detection of the variant by the Genedrive® MT-RNR1 test.



David Budd, CEO of genedrive plc, said: "We are grateful to NICE for their engagement and interest in our innovative technology and pleased that the Genedrive® MT-RNR1 test was selected for this programme following successful publication of the NICE Medtech innovation briefing ("MIB290") in March. The NICE guidance is an important element required to drive uptake and adoption of the test in the NHS by demonstrating the cost-saving efficiencies. The application of Genedrive's technology shows how a rapid, affordable, point-of-care test could impact patients' treatment and quality of life."

[milanr] 06/7/2022 13:26

Don't forget that AIHL is only for new born babies. Not all NHS hospitals will need it. POC no interest at all.

[snowy20] 06/7/2022 13:22

March RNS

First NHS Deployments of the Genedrive® System for Antibiotic Induced Hearing Loss



genedrive plc (AIM: GDR), the near patient molecular diagnostics company, announces that the first six installations of the Genedrive® MT-RNR1 Antibiotic Induced Hearing Loss ("AIHL") system have now been deployed to Manchester University NHS Foundation Trust ("MFT"), with four installations for Saint Mary's Hospital and two at Wythenshawe Hospital (both part of MFT).



The Genedrive® MT-RNR1 System screens infants in an urgent care setting for a genetic mutation that will cause lifelong hearing loss ("Ototoxicity"), when carriers of the mutation are given certain antibiotics. Those that carry the mutation can be given alternative treatments. MFT will become the first NHS trust to implement the technology into routine clinical care. The test will deliver a genetic determination of MT-RNR1 status in 30 minutes, from a simple cheek swab.



The Genedrive MT-RNR1 System is available in the UK and Ireland in cooperation with Inspiration Healthcare (AIM: IHC). Hospitals interested in discovering more about how to manage ototoxicity can visit

hxxps://www.genedrive.com/assays/rnr1-product.php.



Clinicians at MFT, supported through the National Institute for Health Research, Manchester Biomedical Research Centre (Hearing Health, Developing Genetic and Genomic Solutions) partnered with the Company in the development and validation of the innovative MT-RNR1 genetic test.



David Budd, CEO of genedrive plc, said: "Final completion and commissioning of these installations is important for the health and safety of infants being admitted into newborn intensive care units ("NICU"). They are also important as their routine use will serve as a model for other Trust and NICU's looking for innovative ways to improve patient safety and overall outcomes. This is a cornerstone installation for us as we commercialise our unique AIHL assay."